Cargando…

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles

Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to borte...

Descripción completa

Detalles Bibliográficos
Autores principales: Borisov, Nicolas, Sergeeva, Anna, Suntsova, Maria, Raevskiy, Mikhail, Gaifullin, Nurshat, Mendeleeva, Larisa, Gudkov, Alexander, Nareiko, Maria, Garazha, Andrew, Tkachev, Victor, Li, Xinmin, Sorokin, Maxim, Surin, Vadim, Buzdin, Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083158/
https://www.ncbi.nlm.nih.gov/pubmed/33937058
http://dx.doi.org/10.3389/fonc.2021.652063
_version_ 1783685972475510784
author Borisov, Nicolas
Sergeeva, Anna
Suntsova, Maria
Raevskiy, Mikhail
Gaifullin, Nurshat
Mendeleeva, Larisa
Gudkov, Alexander
Nareiko, Maria
Garazha, Andrew
Tkachev, Victor
Li, Xinmin
Sorokin, Maxim
Surin, Vadim
Buzdin, Anton
author_facet Borisov, Nicolas
Sergeeva, Anna
Suntsova, Maria
Raevskiy, Mikhail
Gaifullin, Nurshat
Mendeleeva, Larisa
Gudkov, Alexander
Nareiko, Maria
Garazha, Andrew
Tkachev, Victor
Li, Xinmin
Sorokin, Maxim
Surin, Vadim
Buzdin, Anton
author_sort Borisov, Nicolas
collection PubMed
description Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders): FGFR3, MAF, IGHA2, IGHV1-69, and GRB14. Four of these genes are linked with known immunoglobulin locus rearrangements. We then used five machine learning (ML) methods to build a classifier distinguishing good and poor responders for two cohorts: PAD + VCD (53 patients), and separately VCD (47 patients). We showed that the application of FloWPS dynamic data trimming was beneficial for all ML methods tested in both cohorts, and also in the previous MM bortezomib datasets. However, the ML models build for the different datasets did not allow cross-transferring, which can be due to different treatment regimens, experimental profiling methods, and MM heterogeneity.
format Online
Article
Text
id pubmed-8083158
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80831582021-04-30 Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles Borisov, Nicolas Sergeeva, Anna Suntsova, Maria Raevskiy, Mikhail Gaifullin, Nurshat Mendeleeva, Larisa Gudkov, Alexander Nareiko, Maria Garazha, Andrew Tkachev, Victor Li, Xinmin Sorokin, Maxim Surin, Vadim Buzdin, Anton Front Oncol Oncology Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients respond differently to bortezomib, and new prognostic biomarkers are needed to personalize treatments. However, there is a shortage of clinically annotated MM molecular data that could be used to establish novel molecular diagnostics. We report new RNA sequencing profiles for 53 MM patients annotated with responses on two similar chemotherapy regimens: bortezomib, doxorubicin, dexamethasone (PAD), and bortezomib, cyclophosphamide, dexamethasone (VCD), or with responses to their combinations. Fourteen patients received both PAD and VCD; six received only PAD, and 33 received only VCD. We compared profiles for the good and poor responders and found five genes commonly regulated here and in the previous datasets for other bortezomib regimens (all upregulated in the good responders): FGFR3, MAF, IGHA2, IGHV1-69, and GRB14. Four of these genes are linked with known immunoglobulin locus rearrangements. We then used five machine learning (ML) methods to build a classifier distinguishing good and poor responders for two cohorts: PAD + VCD (53 patients), and separately VCD (47 patients). We showed that the application of FloWPS dynamic data trimming was beneficial for all ML methods tested in both cohorts, and also in the previous MM bortezomib datasets. However, the ML models build for the different datasets did not allow cross-transferring, which can be due to different treatment regimens, experimental profiling methods, and MM heterogeneity. Frontiers Media S.A. 2021-04-15 /pmc/articles/PMC8083158/ /pubmed/33937058 http://dx.doi.org/10.3389/fonc.2021.652063 Text en Copyright © 2021 Borisov, Sergeeva, Suntsova, Raevskiy, Gaifullin, Mendeleeva, Gudkov, Nareiko, Garazha, Tkachev, Li, Sorokin, Surin and Buzdin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Borisov, Nicolas
Sergeeva, Anna
Suntsova, Maria
Raevskiy, Mikhail
Gaifullin, Nurshat
Mendeleeva, Larisa
Gudkov, Alexander
Nareiko, Maria
Garazha, Andrew
Tkachev, Victor
Li, Xinmin
Sorokin, Maxim
Surin, Vadim
Buzdin, Anton
Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title_full Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title_fullStr Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title_full_unstemmed Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title_short Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
title_sort machine learning applicability for classification of pad/vcd chemotherapy response using 53 multiple myeloma rna sequencing profiles
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083158/
https://www.ncbi.nlm.nih.gov/pubmed/33937058
http://dx.doi.org/10.3389/fonc.2021.652063
work_keys_str_mv AT borisovnicolas machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT sergeevaanna machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT suntsovamaria machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT raevskiymikhail machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT gaifullinnurshat machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT mendeleevalarisa machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT gudkovalexander machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT nareikomaria machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT garazhaandrew machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT tkachevvictor machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT lixinmin machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT sorokinmaxim machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT surinvadim machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles
AT buzdinanton machinelearningapplicabilityforclassificationofpadvcdchemotherapyresponseusing53multiplemyelomarnasequencingprofiles